Last reviewed · How we verify

Darunavir/Ritonavir (DRV/r)

Janssen-Cilag S.p.A. · Phase 3 active Small molecule

Darunavir/Ritonavir (DRV/r) is a Protease inhibitor (PI) Small molecule drug developed by Janssen-Cilag S.p.A.. It is currently in Phase 3 development for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.

Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

At a glance

Generic nameDarunavir/Ritonavir (DRV/r)
SponsorJanssen-Cilag S.p.A.
Drug classProtease inhibitor (PI)
TargetHIV protease
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Darunavir binds to HIV protease and inhibits its enzymatic activity, preventing the cleavage of viral polyproteins into functional proteins required for viral replication and assembly. Ritonavir is a potent CYP3A4 inhibitor that dramatically increases darunavir plasma concentrations by reducing hepatic metabolism, allowing for lower and less frequent darunavir dosing while maintaining therapeutic efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Darunavir/Ritonavir (DRV/r)

What is Darunavir/Ritonavir (DRV/r)?

Darunavir/Ritonavir (DRV/r) is a Protease inhibitor (PI) drug developed by Janssen-Cilag S.p.A., indicated for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

How does Darunavir/Ritonavir (DRV/r) work?

Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.

What is Darunavir/Ritonavir (DRV/r) used for?

Darunavir/Ritonavir (DRV/r) is indicated for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.

Who makes Darunavir/Ritonavir (DRV/r)?

Darunavir/Ritonavir (DRV/r) is developed by Janssen-Cilag S.p.A. (see full Janssen-Cilag S.p.A. pipeline at /company/janssen-cilag-s-p-a).

What drug class is Darunavir/Ritonavir (DRV/r) in?

Darunavir/Ritonavir (DRV/r) belongs to the Protease inhibitor (PI) class. See all Protease inhibitor (PI) drugs at /class/protease-inhibitor-pi.

What development phase is Darunavir/Ritonavir (DRV/r) in?

Darunavir/Ritonavir (DRV/r) is in Phase 3.

What are the side effects of Darunavir/Ritonavir (DRV/r)?

Common side effects of Darunavir/Ritonavir (DRV/r) include Diarrhea, Nausea, Headache, Rash, Abdominal pain, Lipid elevation.

What does Darunavir/Ritonavir (DRV/r) target?

Darunavir/Ritonavir (DRV/r) targets HIV protease and is a Protease inhibitor (PI).

Related